The Role of Methadone in HIV Prevention And Treatment
Download
1 / 25

Drug Use and HIV - PowerPoint PPT Presentation


  • 124 Views
  • Uploaded on

The Role of Methadone in HIV Prevention And Treatment Sharon Stancliff, MD Medical Consultant AIDS Institute New York State Department of Health. Drug Use and HIV. Injection of heroin and cocaine is the driving force behind HIV in New York State. Addiction.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Drug Use and HIV' - ferris-kirkland


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

The Role of Methadone in HIV Prevention And TreatmentSharon Stancliff, MDMedical ConsultantAIDS InstituteNew York StateDepartment of Health

NYSDOH/AI


Drug use and hiv

Drug Use and HIV

Injection of heroin and cocaine is the driving force behind HIV in New York State

NYSDOH/AI


Addiction
Addiction

• Opiates interact with receptors for endogenous peptides.

• Short term changes in the dopamine secreting neurons, such as atrophy are documented

• Long term changes are suspected.

NYSDOH/AI


Genetics
Genetics

•Twin and adoption studies show a strong familial trend in alcoholism

•Addictive disorders are common among the families of heroin addicts

•Anthenelli

NYSDOH/AI


Drug addiction is a brain disease alan leshner phd national institute of drug abuse director
“Drug Addiction is a Brain Disease”Alan Leshner, PhDNational Institute of Drug AbuseDirector

NYSDOH/AI


National institute of health

National Institute of Health

“Methadone is the most effective treatment for heroin addiction.”

National Institute of Health Consensus Development Conference on the Medical Treatment of Heroin Addiction

NYSDOH/AI


Methadone
Methadone

•A synthetic opiate with a 24-36 hour half-life

•Methadone Maintenance Treatment (MMT) was first implemented by Dole and Nyswander in the 1960s as most “detoxed” addicts relapsed to heroin use

NYSDOH/AI


Methadone1
Methadone

•Usual effective dose: 80-120 mg range:5mg- >500 Clinical response guide dose

•Rettig, Leavitt

•80-90% of those stopping MMT will return to heroin use so treatment is long term

•Ball, Magura

NYSDOH/AI


Methadone2
Methadone

•Safe during pregnancy

•Kandall

•No known long term detrimental effects

•Novick

•MMT is usually accompanied by counseling and sometimes other requirements

NYSDOH/AI



Reduction in heroin use
Reduction in Heroin Use

•Given a sufficient dose virtually all heroin users will stop using heroin

•At lesser doses heroin use is decreased.

•Ball 1991

NYSDOH/AI


Hiv prevention

HIV Prevention

MMT patients are 3-6 times less likely to become HIV positive when compared to out-of-treatment heroin users.

Metzger, Drucker, Gibson, Hartel

NYSDOH/AI


Reduction in hiv seroconversion a prospective study
Reduction in HIV seroconversion: a prospective study

•Comparison of opiate users in and out of methadone treatment

•Those out of treatment reported more risk behavior for HIV

•In treatment: 3.5% seroconverted, Out-of-treatment 22% seroconverted

•Metzger

NYSDOH/AI


Improved outcome in hiv

HIV positive heroin users on methadone are hospitalized less often and live longer than their counterparts who are not on methadone

Weber, Newschaffer, Laine

Improved outcome in HIV

NYSDOH/AI


Other benefits
Other Benefits often and live longer than their counterparts who are not on methadone

• A fourfold reduction in suicide

• A fourfold reduction in lethal overdose

• Capelhorn

• Reductions in sex work

• Bellis

• Reduction in crime

• Hubbard, Appel

NYSDOH/AI


Issues in methadone prescribing
Issues in Methadone Prescribing often and live longer than their counterparts who are not on methadone

NYSDOH/AI


Over regulation
Over regulation often and live longer than their counterparts who are not on methadone

•Available only in methadone clinics

•Frequent attendance required

•Limited number of slots

•Medical maintenance has been shown to be successful outside of these constraints

NYSDOH/AI


Under dosing
Under Dosing often and live longer than their counterparts who are not on methadone

•A 1995 study of selected MMTPs found an average dose of less than 59mg

•2/3s of the clinics set a dose ceiling of 80-100mgs

•D”Aunno

NYSDOH/AI


Premature discharge
Premature discharge often and live longer than their counterparts who are not on methadone

•A 1995 study found that the majority of clinics encourage detox after only 1 year of treatment

•Relapse can be deadly- Zanis found 8.2% mortality among 110 pts. leaving MMTP but only 1.2% among 397 remaining in treatment

NYSDOH/AI


Misunderstandings about methadone
Misunderstandings about methadone often and live longer than their counterparts who are not on methadone

•Patients often believe that methadone causes bone or liver damage.

•Physicians may have misconceptions about pain management in methadone patients.

•It is also erroneously believed that MMT leads to cocaine use.

NYSDOH/AI


Mmt patients are judged by

often and live longer than their counterparts who are not on methadoneFamily

•Friends

•Physicians

•Social service providers

•Employers

•Politicians

•Drug users

MMT patients are judged by:

NYSDOH/AI


Stigmatization by drug treatment providers
Stigmatization by drug Treatment Providers often and live longer than their counterparts who are not on methadone

•MMT patients are discouraged from speaking at Narcotics Anonymous meetings

•Narcotics Anonymous Bulletin

•Many facilities treating cocaine and alcohol abuse bar methadone

NYSDOH/AI


Role of the primary care provider
Role of the Primary Care Provider often and live longer than their counterparts who are not on methadone

•Education of current and potential MMT patients and their families

•Understanding medical issues such as drug interactions

•Working with clinics to ensure the best possible care for patients

NYSDOH/AI


Drug interactions

DRUGS WHICH MAY LOWER PLASMA LEVELS OF METHADONE often and live longer than their counterparts who are not on methadone

•Phenobarbital

•Carbamazepin (Tegretol)

•Phenytoin (Dilantin )**

•Ritonavir (Norvir)

** Major effect, may require large methadone dose increases

•Nevirapine (Viraimmune)**

•Rifampin**

•Efavirenz (Sustiva)**

•Abacavir (Ziagen)

•ethanol (chronic use)

Drug Interactions

NYSDOH/AI


Drug interactions ii
Drug Interactions II often and live longer than their counterparts who are not on methadone

• DRUGS WHICH MAY INCREASE PLASMA LEVELS OF METHADONE (none are major problems)

• Amitriptyline (Elavil)

• Cimetidine (Tagamet)

• Diazepam (Valium)

• Ethanol ( acute use)

• Ketoconazole (Nizoral)

• Zidovudine (AZT) levels may be increased by methadone.

• DRUGS WHICH ARE CONTRAINDICATED

• Pentazocine (Talwin),

• Tramadol (Ultram)

NYSDOH/AI


ad